Development of a Postbiotic-Based Orodispersible Film to Prevent Dysbiosis in the Oral Cavity
Background: Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial mic...
Saved in:
Published in | Frontiers in bioscience (Elite edition) Vol. 17; no. 1; p. 26987 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Singapore
IMR Press
24.03.2025
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial microorganisms. This work aimed to develop a strategy for preventing dysbiosis in the oral cavity by applying a postbiotic-based orodispersible film. Methods: Lactiplantibacillus plantarum 226V and Lacticaseibacillus paracasei L26 were cultured in De Man–Rogosa–Sharpe (MRS) broth for 48 hours, followed by centrifugation and filtration. Then, the resultant postbiotics were then subjected to various dilutions (10% (v/v), 20% (v/v), 40% (v/v), 60% (v/v) and 100% (v/v)) and co-incubated with Streptococcus mutans. Antimicrobial efficacy, minimal inhibitory concentration, the time required to inhibit S. mutans growth, and antibiofilm properties of the postbiotics were assessed. Subsequently, an orodispersible film comprising polymers and plasticizers, namely Xanthan gum, maltodextrin, and glycerol, was developed as a vehicle for postbiotic delivery. Formulation optimization, physical property evaluation, and cytotoxicity against the TR146 human oral cell line (TR146 cell line) were conducted. Results: Postbiotics demonstrated antimicrobial and antibiofilm activity against S. mutans following 24-hour co-incubation. The minimal inhibitory concentration for combined postbiotics administration was 20% (v/v). Remarkably, 79.6 ± 8.15% inhibition of biofilm formation was achieved using 100% (v/v) of the postbiotic derived from L. plantarum 226V. Incorporating postbiotics did not compromise the dissolution time of orodispersible films, all exceeding 20 minutes. Furthermore, solubility improved following postbiotic addition, facilitating ease of handling. Importantly, postbiotic-impregnated orodispersible films were non-cytotoxic when exposed to the TR146 cell line. Conclusions: These findings underscore the potential of orodispersible films loaded with postbiotics as a promising potential intervention for oral dysbiosis. |
---|---|
AbstractList | Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial microorganisms. This work aimed to develop a strategy for preventing dysbiosis in the oral cavity by applying a postbiotic-based orodispersible film.
226V and
L26 were cultured in De Man-Rogosa-Sharpe (MRS) broth for 48 hours, followed by centrifugation and filtration. Then, the resultant postbiotics were then subjected to various dilutions (10% (v/v), 20% (v/v), 40% (v/v), 60% (v/v) and 100% (v/v)) and co-incubated with
Antimicrobial efficacy, minimal inhibitory concentration, the time required to inhibit
growth, and antibiofilm properties of the postbiotics were assessed. Subsequently, an orodispersible film comprising polymers and plasticizers, namely Xanthan gum, maltodextrin, and glycerol, was developed as a vehicle for postbiotic delivery. Formulation optimization, physical property evaluation, and cytotoxicity against the TR146 human oral cell line (TR146 cell line) were conducted.
Postbiotics demonstrated antimicrobial and antibiofilm activity against
following 24-hour co-incubation. The minimal inhibitory concentration for combined postbiotics administration was 20% (v/v). Remarkably, 79.6 ± 8.15% inhibition of biofilm formation was achieved using 100% (v/v) of the postbiotic derived from
226V. Incorporating postbiotics did not compromise the dissolution time of orodispersible films, all exceeding 20 minutes. Furthermore, solubility improved following postbiotic addition, facilitating ease of handling. Importantly, postbiotic-impregnated orodispersible films were non-cytotoxic when exposed to the TR146 cell line.
These findings underscore the potential of orodispersible films loaded with postbiotics as a promising potential intervention for oral dysbiosis. Background: Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial microorganisms. This work aimed to develop a strategy for preventing dysbiosis in the oral cavity by applying a postbiotic-based orodispersible film. Methods: Lactiplantibacillus plantarum 226V and Lacticaseibacillus paracasei L26 were cultured in De Man–Rogosa–Sharpe (MRS) broth for 48 hours, followed by centrifugation and filtration. Then, the resultant postbiotics were then subjected to various dilutions (10% (v/v), 20% (v/v), 40% (v/v), 60% (v/v) and 100% (v/v)) and co-incubated with Streptococcus mutans. Antimicrobial efficacy, minimal inhibitory concentration, the time required to inhibit S. mutans growth, and antibiofilm properties of the postbiotics were assessed. Subsequently, an orodispersible film comprising polymers and plasticizers, namely Xanthan gum, maltodextrin, and glycerol, was developed as a vehicle for postbiotic delivery. Formulation optimization, physical property evaluation, and cytotoxicity against the TR146 human oral cell line (TR146 cell line) were conducted. Results: Postbiotics demonstrated antimicrobial and antibiofilm activity against S. mutans following 24-hour co-incubation. The minimal inhibitory concentration for combined postbiotics administration was 20% (v/v). Remarkably, 79.6 ± 8.15% inhibition of biofilm formation was achieved using 100% (v/v) of the postbiotic derived from L. plantarum 226V. Incorporating postbiotics did not compromise the dissolution time of orodispersible films, all exceeding 20 minutes. Furthermore, solubility improved following postbiotic addition, facilitating ease of handling. Importantly, postbiotic-impregnated orodispersible films were non-cytotoxic when exposed to the TR146 cell line. Conclusions: These findings underscore the potential of orodispersible films loaded with postbiotics as a promising potential intervention for oral dysbiosis. Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial microorganisms. This work aimed to develop a strategy for preventing dysbiosis in the oral cavity by applying a postbiotic-based orodispersible film.BACKGROUNDOral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial microorganisms. This work aimed to develop a strategy for preventing dysbiosis in the oral cavity by applying a postbiotic-based orodispersible film.Lactiplantibacillus plantarum 226V and Lacticaseibacillus paracasei L26 were cultured in De Man-Rogosa-Sharpe (MRS) broth for 48 hours, followed by centrifugation and filtration. Then, the resultant postbiotics were then subjected to various dilutions (10% (v/v), 20% (v/v), 40% (v/v), 60% (v/v) and 100% (v/v)) and co-incubated with Streptococcus mutans. Antimicrobial efficacy, minimal inhibitory concentration, the time required to inhibit S. mutans growth, and antibiofilm properties of the postbiotics were assessed. Subsequently, an orodispersible film comprising polymers and plasticizers, namely Xanthan gum, maltodextrin, and glycerol, was developed as a vehicle for postbiotic delivery. Formulation optimization, physical property evaluation, and cytotoxicity against the TR146 human oral cell line (TR146 cell line) were conducted.METHODSLactiplantibacillus plantarum 226V and Lacticaseibacillus paracasei L26 were cultured in De Man-Rogosa-Sharpe (MRS) broth for 48 hours, followed by centrifugation and filtration. Then, the resultant postbiotics were then subjected to various dilutions (10% (v/v), 20% (v/v), 40% (v/v), 60% (v/v) and 100% (v/v)) and co-incubated with Streptococcus mutans. Antimicrobial efficacy, minimal inhibitory concentration, the time required to inhibit S. mutans growth, and antibiofilm properties of the postbiotics were assessed. Subsequently, an orodispersible film comprising polymers and plasticizers, namely Xanthan gum, maltodextrin, and glycerol, was developed as a vehicle for postbiotic delivery. Formulation optimization, physical property evaluation, and cytotoxicity against the TR146 human oral cell line (TR146 cell line) were conducted.Postbiotics demonstrated antimicrobial and antibiofilm activity against S. mutans following 24-hour co-incubation. The minimal inhibitory concentration for combined postbiotics administration was 20% (v/v). Remarkably, 79.6 ± 8.15% inhibition of biofilm formation was achieved using 100% (v/v) of the postbiotic derived from L. plantarum 226V. Incorporating postbiotics did not compromise the dissolution time of orodispersible films, all exceeding 20 minutes. Furthermore, solubility improved following postbiotic addition, facilitating ease of handling. Importantly, postbiotic-impregnated orodispersible films were non-cytotoxic when exposed to the TR146 cell line.RESULTSPostbiotics demonstrated antimicrobial and antibiofilm activity against S. mutans following 24-hour co-incubation. The minimal inhibitory concentration for combined postbiotics administration was 20% (v/v). Remarkably, 79.6 ± 8.15% inhibition of biofilm formation was achieved using 100% (v/v) of the postbiotic derived from L. plantarum 226V. Incorporating postbiotics did not compromise the dissolution time of orodispersible films, all exceeding 20 minutes. Furthermore, solubility improved following postbiotic addition, facilitating ease of handling. Importantly, postbiotic-impregnated orodispersible films were non-cytotoxic when exposed to the TR146 cell line.These findings underscore the potential of orodispersible films loaded with postbiotics as a promising potential intervention for oral dysbiosis.CONCLUSIONSThese findings underscore the potential of orodispersible films loaded with postbiotics as a promising potential intervention for oral dysbiosis. |
Author | Oliveira, Cláudia S Tavaria, Freni K Rebelo, Mariana B |
Author_xml | – sequence: 1 givenname: Mariana B orcidid: 0009-0002-6228-6545 surname: Rebelo fullname: Rebelo, Mariana B – sequence: 2 givenname: Cláudia S orcidid: 0000-0002-0113-9528 surname: Oliveira fullname: Oliveira, Cláudia S – sequence: 3 givenname: Freni K orcidid: 0000-0002-6273-6668 surname: Tavaria fullname: Tavaria, Freni K |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40150984$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kU1PIzEMhqMVK76Ww_6BVY5wGMiHwyRHKBSQkOCwe0RRJnUgaGbSTaZI_fdELcUXW9bj95XtI7I3phEJ-c3ZueRMy4v59a24NLr9QQ65AdUwxfTergYDB-SklHdW41JxafQ-OQDGFTMaDsnLDX5gn5YDjhNNgTr6nMrUxTRF31y7ggv6lNMiliXmErse6Tz2A50Sfc51sg7drEvFSyw0jnR6w8q7ns7cR5zWv8jP4PqCJ1_5mPyb3_6d3TePT3cPs6vHxgvB2kaFANB60WkjlfO8CyE4FSRTYLyDYILvQgvadzoYAb7lwgCAbtGgcxrkMXnY6i6Se7fLHAeX1za5aDeNlF-ty3WjHm3HDHiUIaAUUC-lg1Ki6jAtjBOSVa3TrdYyp_8rLJMdYvHY927EtCpWci1AM7ax_fOFrroBF9_Gu_NW4GwL-JxKyRi-Ec7s5nt29z35CZ4XihA |
Cites_doi | 10.7717/peerj.12586. 10.1038/s41598-022-22875-w. 10.1038/s41598-020-78971-2. 10.4103/jisp.jisp_114_21. 10.1007/s40496-014-0041-8 10.33549/physiolres.934967 10.3390/ijms222413475. 10.3390/ph15070844. 10.3390/microorganisms10071326. 10.3390/ph12010032. 10.3389/fmicb.2021.617485. 10.1038/s41598-020-80921-x. 10.4317/medoral.21494. 10.1136/bmj.298.6676.779. 10.1007/s10068-021-01009-4. 10.3390/antibiotics11070880. 10.1016/j.crfs.2022.100413. 10.3390/biom12111640. 10.3389/froh.2022.884683. 10.3390/ma15103591. 10.1177/0895937409335626. 10.3390/md20050335. 10.3389/fvets.2020.602280. 10.3390/nu15020291. 10.3390/ma14174872. 10.1038/s41522-022-00307-x. 10.3390/pharmaceutics14081621. 10.1016/j.ifset.2016.10.010 10.1111/prd.12366. 10.3390/diagnostics11081376. 10.3389/fcimb.2020.00397. 10.3390/biom12050729. 10.3390/pharmaceutics13070998. 10.3390/nu14245296. 10.1371/journal.pone.0263851. 10.1155/2014/952970. 10.1007/s12088-019-00828-8. 10.1038/s41575-021-00440-6. 10.3390/pharmaceutics12070657. 10.3390/microorganisms9020428. 10.15226/sojmid.2013.00114 10.1186/s12934-020-01426-w. 10.3389/fphar.2023.1152588. 10.1007/s12602-023-10045-x. 10.4103/2230-973X.114897. |
ContentType | Journal Article |
Copyright | 2025 The Author(s). Published by IMR Press. |
Copyright_xml | – notice: 2025 The Author(s). Published by IMR Press. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
DOI | 10.31083/FBE26987 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1945-0508 |
ExternalDocumentID | oai_doaj_org_article_b094ce3ffe3245088f552e9e0829a230 40150984 10_31083_FBE26987 |
Genre | Journal Article |
GrantInformation_xml | – fundername: National Funds from Fundação para a Ciência e a Tecnologia (FCT) grantid: UIDB/50016/2020 |
GroupedDBID | --- 3IV 53G AAYXX ALMA_UNASSIGNED_HOLDINGS CITATION F5P GROUPED_DOAJ CGR CUY CVF ECM EIF EMOBN NPM 7X8 |
ID | FETCH-LOGICAL-c2207-5ff447c2b8935ac1bfffa5f30549ca4f9fcbf748cb8f924c712944487e9eaa843 |
IEDL.DBID | DOA |
ISSN | 1945-0494 1945-0508 |
IngestDate | Wed Aug 27 00:34:01 EDT 2025 Sat Mar 29 10:09:41 EDT 2025 Sat Aug 16 01:30:50 EDT 2025 Tue Jul 01 05:14:15 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | oral dysbiosis antibiofilm capacity postbiotics orodispersible films |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 2025 The Author(s). Published by IMR Press. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2207-5ff447c2b8935ac1bfffa5f30549ca4f9fcbf748cb8f924c712944487e9eaa843 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0009-0002-6228-6545 0000-0002-6273-6668 0000-0002-0113-9528 |
OpenAccessLink | https://doaj.org/article/b094ce3ffe3245088f552e9e0829a230 |
PMID | 40150984 |
PQID | 3182480084 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_b094ce3ffe3245088f552e9e0829a230 proquest_miscellaneous_3182480084 pubmed_primary_40150984 crossref_primary_10_31083_FBE26987 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-03-24 |
PublicationDateYYYYMMDD | 2025-03-24 |
PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-24 day: 24 |
PublicationDecade | 2020 |
PublicationPlace | Singapore |
PublicationPlace_xml | – name: Singapore |
PublicationTitle | Frontiers in bioscience (Elite edition) |
PublicationTitleAlternate | Front Biosci (Elite Ed) |
PublicationYear | 2025 |
Publisher | IMR Press |
Publisher_xml | – name: IMR Press |
References | ref13 ref35 ref12 ref34 ref15 ref37 ref14 ref36 ref31 ref30 ref11 ref33 ref10 ref32 ref2 ref1 ref17 ref39 ref16 ref38 ref19 ref18 ref24 ref23 ref45 ref26 ref25 ref20 ref42 ref41 ref22 ref44 ref21 ref43 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref40 |
References_xml | – ident: ref17 doi: 10.7717/peerj.12586. – ident: ref22 doi: 10.1038/s41598-022-22875-w. – ident: ref7 doi: 10.1038/s41598-020-78971-2. – ident: ref27 doi: 10.4103/jisp.jisp_114_21. – ident: ref6 doi: 10.1007/s40496-014-0041-8 – ident: ref11 doi: 10.33549/physiolres.934967 – ident: ref14 doi: 10.3390/ijms222413475. – ident: ref32 doi: 10.3390/ph15070844. – ident: ref5 doi: 10.3390/microorganisms10071326. – ident: ref38 doi: 10.3390/ph12010032. – ident: ref42 doi: 10.3389/fmicb.2021.617485. – ident: ref12 doi: 10.1038/s41598-020-80921-x. – ident: ref26 doi: 10.4317/medoral.21494. – ident: ref3 doi: 10.1136/bmj.298.6676.779. – ident: ref33 doi: 10.1007/s10068-021-01009-4. – ident: ref1 doi: 10.3390/antibiotics11070880. – ident: ref20 doi: 10.1016/j.crfs.2022.100413. – ident: ref19 doi: 10.3390/biom12111640. – ident: ref30 doi: 10.3389/froh.2022.884683. – ident: ref37 doi: 10.3390/ma15103591. – ident: ref13 doi: 10.1177/0895937409335626. – ident: ref41 doi: 10.3390/md20050335. – ident: ref21 doi: 10.3389/fvets.2020.602280. – ident: ref24 doi: 10.3390/nu15020291. – ident: ref29 doi: 10.3390/ma14174872. – ident: ref4 doi: 10.1038/s41522-022-00307-x. – ident: ref31 doi: 10.3390/pharmaceutics14081621. – ident: ref40 doi: 10.1016/j.ifset.2016.10.010 – ident: ref10 doi: 10.1111/prd.12366. – ident: ref2 doi: 10.3390/diagnostics11081376. – ident: ref35 doi: 10.3389/fcimb.2020.00397. – ident: ref23 doi: 10.3390/biom12050729. – ident: ref28 doi: 10.3390/pharmaceutics13070998. – ident: ref18 doi: 10.3390/nu14245296. – ident: ref39 doi: 10.1371/journal.pone.0263851. – ident: ref43 doi: 10.1155/2014/952970. – ident: ref8 doi: 10.1007/s12088-019-00828-8. – ident: ref15 doi: 10.1038/s41575-021-00440-6. – ident: ref45 doi: 10.3390/pharmaceutics12070657. – ident: ref9 doi: 10.3390/microorganisms9020428. – ident: ref36 doi: 10.15226/sojmid.2013.00114 – ident: ref25 doi: 10.1186/s12934-020-01426-w. – ident: ref34 doi: 10.3389/fphar.2023.1152588. – ident: ref16 doi: 10.1007/s12602-023-10045-x. – ident: ref44 doi: 10.4103/2230-973X.114897. |
SSID | ssj0000651398 |
Score | 2.3572788 |
Snippet | Background: Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that... Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the... |
SourceID | doaj proquest pubmed crossref |
SourceType | Open Website Aggregation Database Index Database |
StartPage | 26987 |
SubjectTerms | Anti-Bacterial Agents - pharmacology antibiofilm capacity Biofilms Cell Line Dysbiosis - prevention & control Humans Hydrogen-Ion Concentration Lactobacillaceae - physiology Microbial Viability Mouth - microbiology oral dysbiosis orodispersible films postbiotics Streptococcus - physiology streptococcus mutans |
Title | Development of a Postbiotic-Based Orodispersible Film to Prevent Dysbiosis in the Oral Cavity |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40150984 https://www.proquest.com/docview/3182480084 https://doaj.org/article/b094ce3ffe3245088f552e9e0829a230 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSwMxEA7Sg3gR39YXUbyGbrNJNzna2lIE9WKhF1mSNAMLdVfc9uC_d7K7LXsRL16XgQkzycw3m8k3hNw7RGyca8G49sCElzEzXHqWcOUicNHAQdXl-zKYzsTTXM5bo75CT1hND1wbrmex_nA-BvCY-gOaACm51z68CTWIn0P0xZzXKqbqGCwR2lTv4LSQLJCg1LRCiGZU3JsMx3ygQxtdKxlVnP2_A80q4UwOyH6DFOlDvcJDsuPzI7L73NyFH5P3Vr8PLYAaGgbv2qxAeTbE5LSgrxgds0AFjvt-6ekkW37QVUEb2ib6-F2ieJmVNMspAkGUR4UjE8ZJnJDZZPw2mrJmWAJznEcJkwBCJI5bBCDSuL4FACMBj7PQzgjQ4CwkQjmrAGsul2CiF1ibJWhLY5SIT0knL3J_Tih6ySslbRTrhZAuQoii1MLz_iCyPJLQJXcbq6WfNSdGirVEZdp0Y9ouGQZ7bgUCjXX1AZ2bNs5N_3Jul9xuvJHitg93GSb3xbpEZYoLFaYBdMlZ7aatKhH-4mglLv5jCZdkj4eRv1HMuLgindXX2l8jDlnZm2rL_QB63Nap |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+a+Postbiotic-Based+Orodispersible+Film+to+Prevent+Dysbiosis+in+the+Oral+Cavity&rft.jtitle=Frontiers+in+bioscience+%28Elite+edition%29&rft.au=Mariana+B+Rebelo&rft.au=Cl%C3%A1udia+S+Oliveira&rft.au=Freni+K+Tavaria&rft.date=2025-03-24&rft.pub=IMR+Press&rft.issn=1945-0494&rft.volume=17&rft.issue=1&rft.spage=26987&rft_id=info:doi/10.31083%2FFBE26987&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_b094ce3ffe3245088f552e9e0829a230 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1945-0494&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1945-0494&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1945-0494&client=summon |